Bill Haddad

Bill Haddad

Benzinga Editor

Here's Why Farfetch Shares Are Rallying After Hours
AVROBIO Announces Clinical Data For Gaucher Disease Gene Therapy; Says 'Following positive feedback from FDA and MHRA, registrational, global Phase 2/3 clinical trial for GD3 planned for second half 2023'
'F1 renews with ESPN for U.S. media rights through 2025' -Sports Business Journal
Market On Close Imbalance: $320M To Sell Side
Meme-Stock Probe Finds Robinhood Woes Were Worse Than It Let On
Southwest Airlines, On Scotus Decision, Says Not Making Any Immediate Changes To Our Health Benefits
This Day In Market History: S&P 500 Index Overhauled To Market Cap-Weighted Structure
Why Spirit Airlines Shares Are Taking Off
Why MongoDB Shares Spiked After Hours
Microvast Confirms Revenue Guidance For FY21 Will Be Within Previously Announced Range Of $145M-$155M vs $146.68M Est.
Sensata Technologies Sees Q1 Adj. EPS $0.70-$0.78 vs $0.88 Est., Sales $935M-$975M vs $963.59M Est.; Sees FY22 Adj. EPS $3.80-$4.06 vs $4.05 Est., Sales $4.215B-$4.275B vs $4.12B Est.
Sensata Technologies Q4 Adj. EPS $0.87 Beats $0.80 Est., Sales $934.6M Beat $916.37M Est.
Eneti Inc. Announces It Has Discontinued Its Discussions With A US Shipyard To Turbine Installation Vessel; Co. Announces New Contract Awards For Seajacks
Fed's Daly Says Balancing Fed's Two Mandates Is Always The Challenge, Says Not Comfortable With High Inflation
Why Shares Of Affirm Dipped On Thursday
ESSA Pharma Announces First Patient Dosed In Phase 1/2 Clinical Trial Of EPI-7386 In Combination With Enzalutamide In Patients With Metastatic Castration-Resistant Prostate Cancer
Gamida Cell Says Planning To Initiate Rolling BLA Submission For Omidubicel; Full BLA Submission On Track For 1H 2022
Ginkgo Bioworks Announces Acquisition Of Massachusetts COVID-19 Testing Provider Project Beacon COVID-19 LLC; Terms Not Disclosed
Regeneron Announces FDA Accepts For Review Libtayo In Combination With Chemotherapy For First-Line Treatment Of Advanced NSCLC
Osmotica Pharmaceuticals Says Q4 Net Sales For UNPEEQ Targeted To Range From $20M-$25M